INNV-03. SAFETY AND ADVERSE EVENT PROFILE OF TUMOR TREATING FIELDS USE IN THE EMEA REGION A REAL-WORLD DATA ANALYSIS

INTRODUCTION Tumor Treating Fields (TTFields) is approved for the treatment of newly diagnosed and recurrent glioblastoma. The efficacy and safety of TTFields in newly diagnosed GBM was previously demonstrated in the EF-14 phase 3 trial (n=695). Optune + temozolomide significantly improved survival outcomes compared to temozolomide alone (median OS: 20.9 vs 16.0 months, p